To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

NCT06898060 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

282

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG: QLG2128
DRUG: Teriparatide Injection

Sponsor

Qilu Pharmaceutical Co., Ltd.